<DOC>
	<DOCNO>NCT01581060</DOCNO>
	<brief_summary>The aim part 1 study determine optimal biological dose ( OBD ) maximum tolerate dose ( MTD ) WX-554 recommend dose/dose schedule chronic treatment part 2 . The aim part 2 determine safety tolerability chronic treatment WX-554 .</brief_summary>
	<brief_title>Phase I/II Dose-escalation Study Investigate Safety Pharmacokinetics/ Pharmacodynamics WX-554 Patients With Solid Tumours</brief_title>
	<detailed_description />
	<criteria>1 . Patients advance , metastatic and/or progressive solid tumour effective standard therapy available . 2 . Evaluable measurable disease 3 . Has normal organ function ; great 2 ECOG Performance Scale 4. life expectancy &gt; 3 month 5. negative hCG test woman childbearing potential 1 . Patients receive investigational anticancer drug within 4 week start study 2 . Patients receive major surgery , radiotherapy , immunotherapy within 4 week start study 3 . Clinically significant , unresolved toxicity previous anticancer therapy Patients 4 . Patients previously receive MEK inhibitor 5 . Presence active gastrointestinal disease condition interfere significantly absorption , distribution , metabolism , excretion drug . 6 . Known medical history retinal vein occlusion , intraocular pressure great 21 mm Hg patient consider risk retinal vein thrombosis . 7 . Known HIV positivity active hepatitis B C infection . 8 . History clinically significant cardiac condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>